PROGESTIN DOMINANT IMPACT CONSOLIDATED ORAL CONTRACEPTION ON ADVANCEMENT OF UTERINE FIBROID

Dr. Humna Mian Faiz Rasul, Dr. Gulshan Tahera, Dr. Khadija Latif

Abstract


Background: Joined oral contraception obstructs the endogenous ovarian steroid emission that settles the hormonal conditions. Progestin dominant, monophasic, contraceptives may prompt relapse of estrogen dependent infections, for example uterine fibroids and endometriosis.

Objective: The aim of this investigation was to report the improvement of uterine fibroids presented to the impact of joined oral preventative with progestin dominancy.

Materials and Methods: This randomized controlled single blind prospective observational study was carried out at Sir Ganga Ram Hospital, Lahore during the period from 01.07.2017 to 31.07.2018. Total 258 patients were selected for the study, which were randomly partitioned into two groups: 194 females with one or various uterine fibroids treated minimalistically with monophasic hormonal pills containing ethinylestradiol 20mcg and gestodene 75mcg were watched for a time of handsome period and 64 females in the control gathering.

Results: In 150 patients (77.31% vs 31.21% of untreated controls), relapse or no development was enrolled. In 44 (22.7%) patients, the span of myoma expanded, monthly cycle anomaly and overwhelming bleeding proceeded or worsened. 44 (68.8%) out of 64 patients kept experiencing dysfunctional bleeding and pain of abdominal allied with uterine fibroids in untreated controls and asked for another method of treatment. The adjustments in myomas volume between the exploratory and control gather significant statistically p value 0.044.  

Conclusion: Utilization of hormonal contraceptive low dose with progestin dominancy can prompt significant decrease in volume of myoma.

Key words: Progestin Dominancy, Contraception, Growth, Regression, Myoma, Uterine Fibroids.


Full Text:

PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.